

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3576821

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Gregroy Hardee	06/01/2010
RECEIVING PARTY DATA	
Name:	SANTARIS PHARMA A/S
Street Address:	FREMTIDSVEJ 3
City:	HOERSHOLM
State/Country:	DENMARK
Postal Code:	2970
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14886860
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 542-5070
Email:	apsi@fr.com
Correspondent Name:	ANITA L. MEIKLEJOHN
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	22460-0053002
NAME OF SUBMITTER:	MARY FLORCZAK
SIGNATURE:	/Mary Florczak/
DATE SIGNED:	10/20/2015
Total Attachments: 2	
source=Hardee to Santaris#page1.tif	
source=Hardee to Santaris#page2.tif	

ASSIGNMENT

For valuable consideration of 1 (one) US dollar, I, **Gregory E. Hardee**, 12951 Caminito En Flor, Del Mar, CA 92014, UNITED STATES hereby assign to:

Santaris Pharma A/S

a corporation of Denmark having a place of business at:

Kogle Allé 6
2970 Hørsholm
Denmark


and its successors and assigns (collectively hereinafter called "the Assignee"), the entire right and title and interest throughout the world to the inventions which are subject to the United States Provisional Patent Application 61/253,090 entitled "*Oral Delivery of Therapeutically Effective LNA Oligonucleotides*", filed on October 20, 2009, and to the United States Provisional Patent Application 61/321,892 entitled "*Oral Delivery of Therapeutically Effective LNA Oligonucleotides*", filed on April 8, 2010, this assignment including said application, any and all patents, patent applications, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and I authorize the Assignee to apply in all countries in my name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements; and I agree for myself and my respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.

Furthermore, I hereby agree to execute without additional compensation the legal documents, such as assignments, declarations, Power of Attorneys and the like that are required for Santaris

Pharma A/S or its successors to seek and maintain the above patent rights derived from, or claiming priority from United States Provisional Patent Application 61/253,090 and United States Provisional Patent Application 61/321,892.

Furthermore, on the request of Santaris Pharma A/S or its successor in title, I hereby agree to assist in technical and scientific aspects of prosecution and post-grant proceedings to the extent that the request is not contradictory to prior obligations to third parties.

Signed the 1st day of June 2010



Gregory E. Haldee, PhD.